**Core Concept:** Cholesterol synthesis is an essential process in mammals, regulated by enzymes and controlled by feedback mechanisms. The initial step involves the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate.

**Why the Correct Answer is Right:**
The correct answer, **Doxorubicin**, is an antineoplastic agent (antimycotic) used in cancer chemotherapy. It is an anthracycline antibiotic that interferes with DNA and RNA synthesis, inhibiting topoisomerase II, leading to cell death and anti-tumor activity.

**Why Each Wrong Option is Incorrect:**
A. **Lovastatin** is a hydroxymethylglutaryl-CoA reductase inhibitor, a statin used to lower cholesterol levels. It does not inhibit the initial step of cholesterol synthesis, as it targets the later steps in the process.

B. **Simvastatin** is another statin that inhibits HMG-CoA reductase, preventing cholesterol synthesis and lowering blood cholesterol levels. However, it is not the correct answer for this question as it targets the same enzyme as lovastatin.

C. **Mepyramine** is a histamine H1 receptor antagonist, commonly used as an antihistamine. It does not inhibit the initial step of cholesterol synthesis and is not a relevant drug in this context.

**Clinical Pearl:**
Understanding the role of HMG-CoA reductase inhibitors in cholesterol regulation is essential for clinical practice. These drugs are essential in managing dyslipidemia and reducing cardiovascular risk by lowering low-density lipoprotein (LDL) cholesterol levels. However, they are not directly related to the inhibition of cholesterol synthesis in the context of the question.

**Correct Answer:** C. **Mepyramine** is a histamine H1 receptor antagonist, commonly used as an antihistamine. It does not inhibit the initial step of cholesterol synthesis and is not a relevant drug in this context.